Brand dashboard

ZENVARA

US launch · week-of-launch 54 · NSCLC 1L PD-L1≥50%

Latest week

2026-05-29

4-wk avg variance: -17.7%

TRx this week

2,088

vs plan 2,499 (-16.4%)

NBRx this week

132

21% of NRx — new-to-brand

Commercial coverage

52.6%

Medicare 42.7% · Medicaid 33.4%

Field calls (trailing quarter)

4,166

1618 hematology & oncology, 883 other

Plan vs actual — TRx (full launch year, WK1-54)

Plan curve in zinc, actual TRx in blue. First gap opens WK14 (Aug 2025 Aetna signal). Narrows in Q3 with Cigna ramp. Widens again in Q4 as UHC PA latency hits.

raw json ↗

Coverage by major payer

raw json ↗

UnitedHealthcare Choice Plus PPO
UnitedHealth Group · OptumRx
29.3M · Commercial
Covered with Restrictions
PA
Anthem BCBS PPO
Elevance Health · CarelonRx
22.1M · Commercial
Covered with Restrictions
PA
Aetna Open Access PPO
CVS Health · CVS Caremark
16.8M · Commercial
Covered with Restrictions
PASTLA
Cigna Open Access Plus
The Cigna Group · Express Scripts
13.3M · Commercial
Covered with Restrictions
PA
California Medi-Cal
State of California · Magellan Rx
12.6M · Medicaid FFS
Covered with Restrictions
PA
Kaiser Permanente
Kaiser Permanente · Kaiser (internal)
12.2M · Commercial
Covered with Restrictions
PAST
UnitedHealthcare Medicare Advantage
UnitedHealth Group · OptumRx
10.4M · Medicare Part D
Covered with Restrictions
PA
TRICARE Pharmacy
U.S. Department of Defense · Express Scripts
10M · Government
Exception-Eligible
ST
Veterans Affairs (VA NPS)
U.S. Department of Veterans Affairs · VA Pharmacy Benefits Management
9.1M · Government
Covered with Restrictions
PAQL
Humana Gold Plus HMO
Humana · Humana Pharmacy Solutions
8.9M · Medicare Part D
Covered with Restrictions
PALA

Recent payer events

raw ↗

2025-09-14 · Anthem BCBS
tier changed
Anthem BCBS moved ZENVARA from preferred to non-preferred tier.
lives: 18,662,282 · rel: 70%
2025-09-14 · CMS
coverage decision
CMS issued coverage decision for ZENVARA in NSCLC.
lives: 3,206,158 · rel: 74%
2025-09-13 · OptumRx
excluded
OptumRx excluded ZENVARA from 2026 formulary effective 2025-10-19.
lives: 63,999,900 · rel: 81%
2025-09-13 · ICER
value assessment final
ICER published final value assessment for ZENVARA in NSCLC.
lives: 60,385,716 · rel: 76%
2025-09-10 · OptumRx Medicare
removed
OptumRx Medicare removed ZENVARA from formulary effective 2025-10-20.
lives: 9,218,920 · rel: 61%
2025-09-10 · G-BA (Germany)
coverage decision
G-BA (Germany) issued coverage decision for ZENVARA in NSCLC.
lives: 16,457,202 · rel: 74%

Field activity — trailing quarter

By territory

southeast1153 · 80u · avg 11.2m
northeast1092 · 80u · avg 11.1m
midwest1005 · 80u · avg 10.6m
west916 · 80u · avg 11.3m

By specialty

Hematology & Oncology1618
Medical Oncology883
Radiation Oncology637
Pulmonary Disease348
Surgical Oncology268
Pathology262

Storyline arcs touching ZENVARA

05-15 14:02
Just opened WK19 NPA. NBRx -14% in NE, -16% trailing four weeks. We need to talk.
Marco Reyes · uhc-pa-escalation
05-14 18:30
Created: ASCO 2026 Readout — Competitive Implications
Jordan Patel · asco-readout
05-14 16:00
Cigna formulary win confirmed — Tier 3 preferred with PA, effective Jul 1.
Marco Reyes · cigna-win
05-13 09:42
Heads up: 4 abstracts in our class lift embargo over the next ~24h.
Jordan Patel · asco-readout
05-12 10:00
Competitor X ASCO abstract dropped — Kaplan-Meier at 18.2 mo, our last cut was 17.6.
Jordan Patel · asco-readout
05-11 10:30
Updated: Weekly Launch Tracker — WK19
Marco Reyes · uhc-pa-escalation
05-11 09:15
UHC PA turnaround slipped to 9 days in NE region — anyone else seeing this?
Aisha Bello · uhc-pa-escalation
05-11 08:00
NPA WK19 data published (week ending 2026-05-08)
IQVIA NPA feed · uhc-pa-escalation

Open full timeline →